Omthera Pharmaceuticals is a Bedminster, NJ–based pharmaceuticals company focused on the clinical development of therapies for dyslipidemia. Its lead compound is Epanova, a novel omega‑3 fatty acid intended to address elevated triglyceride levels and cardiovascular risk. The company intends to use new capital to fund Phase 3 clinical development of Epanova and for general corporate purposes. Omthera raised $33.9M in a Series B round led by New Enterprise Associates with participation from Sofinnova Partners. With this latest round the company has raised approximately $40.4M in venture capital since commencement of operations in 2009. Founded in 2008 by CEO Jerry Wisler, the company also added NEA General Partner David M. Mott to its board in conjunction with the funding. Omthera Pharmaceuticals is a Bedminster, New Jersey-based pharmaceutical company focused on developing new dyslipidemia therapies. Its lead product candidate, Epanova, is a novel omega-3 fatty acid formulation containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) that has demonstrated promising triglyceride-lowering effects in earlier clinical trials. Epanova has also shown an excellent safety and tolerability profile. Omthera holds worldwide rights to Epanova and plans to use proceeds from its recent financing to advance the candidate's clinical development. The company closed a $6.5M Series A round led by Sofinnova Partners and announced commencement of operations. The management team includes Jerry Wisler as president and chief executive officer and Michael Davidson, M.D., as chief medical officer.

Total raised

$40M

Funding rounds

2

Latest round

Series B

Latest activity

Mar 2011